Article

GLP-1s and Mental Health: What Is Emerging Research Telling Us?

Oct 27, 2026

In this article

A New Chapter in the GLP-1 Story

GLP-1 receptor agonists (GLP-1 RAs) have moved quickly from medicines primarily associated with type 2 diabetes and weight management to one of the most closely watched areas of modern medicine.

Their effects on appetite, glucose regulation and body weight are well established across several approved uses. GLP-1 receptors are found in areas of the brain involved in appetite, reward and motivation. This has led researchers to investigate whether GLP-1 signaling might also influence processes associated with mood, cognition, reward and addiction-related behaviors.

The important point is not that GLP-1 medicines have suddenly become “mental health drugs” as the evidence does not support that conclusion. Rather, they are giving researchers an opportunity to investigate something potentially more fundamental: how closely connected are metabolic health, brain function and mental wellbeing?

A 2025 systematic review and meta-analysis covering 80 randomized clinical trials and more than 107,000 participants found no evidence that GLP-1 RAs increased serious or non-serious psychiatric adverse events or worsened depressive symptoms compared with placebo. Treatment was also associated with improvements in several quality-of-life measures and reductions in restrained and emotional eating.

The findings provide further evidence against an increased psychiatric safety risk identified in the analysis.

From Safety Signal to Scientific Question

Mental health became a prominent part of the GLP-1 conversation following reports of suicidal thoughts and behaviour among some people taking these medicines. The subsequent regulatory investigations highlight an important principle in a rapidly evolving area of medicine: a safety signal is a reason to investigate, not a conclusion in itself.

In January 2026, the US Food and Drug Administration (FDA) announced that its comprehensive evaluation had not identified an increased risk of suicidal ideation or behaviour associated with GLP-1 receptor agonists (GLP-1 RAs). The assessment included 91 placebo-controlled trials involving 107,910 participants, alongside a Sentinel System study involving more than 2.2 million people. The FDA also reported no increased risk of other relevant psychiatric adverse events, including anxiety, depression, irritability or psychosis.

The European Medicines Agency (EMA) reached a similar conclusion in 2024, finding that the available evidence did not support a causal association between GLP-1 RAs and suicidal or self-injurious thoughts and actions.

Together, these findings provide reassurance about the specific psychiatric risks investigated. They also demonstrate how understanding of medicine safety develops through the combined analysis of spontaneous reports, real-world data, controlled clinical trials and ongoing pharmacovigilance.

With these initial safety concerns investigated, attention is also turning to a broader scientific question: could GLP-1 signalling have other effects on processes associated with mental health, cognition and behaviour?

Exploring the Relationship Between GLP-1s and Mental Health

Emerging research is beginning to investigate this question, examining potential relationships between GLP-1 signalling and specific aspects of mental health. While the evidence remains preliminary, depression, cognition, reward processing and motivation are among the areas attracting scientific interest.

One area of investigation is depression. In 2026, a secondary analysis of a randomised clinical trial examined whether oral semaglutide could influence reward-related dysfunction in people with major depressive disorder and overweight or obesity.

Cognition is another area under investigation. Another 2026 randomised clinical trial examined the effects of semaglutide on cognitive function in adults with major depressive disorder and overweight or obesity. Although semaglutide did not improve the trial’s primary measure of executive function, a prespecified secondary analysis suggested improvements in global cognition.

Complementing these findings, a 2026 retrospective cohort study involving more than 13,000 people with psychiatric diagnoses found that semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms over 12 months than several comparator treatments. However, the researchers noted that further randomised trials are needed to establish causality and determine the clinical significance of these findings.

Taken together, these studies illustrate both the potential and the limitations of the current evidence. Clinical trials can help assess specific outcomes under controlled conditions, while observational studies can identify patterns in real-life healthcare data. Neither early findings nor observed associations should be interpreted as proof of a direct therapeutic effect.

The priority now is to understand which findings are robust, which warrant further investigation and what they may ultimately mean for Patients.

The Reward System: An Unexpected Research Frontier

Perhaps the most thought-provoking development is the growing interest in the brain’s reward pathways.

GLP-1 receptors are expressed in regions involved in appetite, reward and motivation which has prompted researchers to ask whether GLP-1 signaling might influence responses to other rewarding stimuli beyond only food. Alcohol use disorder is providing some of the early clinical research into this question.

In a 2025 randomized clinical trial involving 48 adults with alcohol use disorder, low-dose semaglutide reduced alcohol consumption in a laboratory task and reduced alcohol craving, although it did not significantly change every measure of drinking. The authors concluded that larger trials were warranted.

More recently, a 26-week randomized trial involving 108 treatment-seeking people with alcohol use disorder and obesity reported a reduction in heavy drinking days with semaglutide compared with placebo. These findings are preliminary and do not establish semaglutide as a treatment for alcohol use disorder.

These findings do not, on the basis of these trials alone, establish GLP-1 RAs as treatments for alcohol use disorder. They do, however, make the reward system an increasingly important research frontier. Researchers are beginning to investigate whether GLP-1 signaling may be associated with aspects of reward, reinforcement and motivation more broadly.

The Biology Is Interesting. The Human Experience Is More Complicated.

There is an understandable temptation with a rapidly developing drug class to look for a single explanatory mechanism, but mental health rarely works that way.

Changes in mood, cognition or wellbeing can be influenced by weight loss, metabolic health, physical symptoms, social experiences, expectations and changes in behavior, alongside any direct effects of GLP-1 signaling. Untangling these relationships to understand correlation or causation will require careful research design.

A 2025 review of mental health outcomes in obesity interventions concluded that current evidence is broadly reassuring, while also suggesting areas of potential benefit. It highlighted the shortage of long-term data and the need for future randomized trials to include mental health as a prespecified outcome. And the story is not uniformly positive.

In 2026, two large phase 3 trials involving almost 3,800 people with early Alzheimer’s disease found that oral semaglutide did not slow clinical progression compared with placebo. That result is an important counterpoint to the excitement around GLP-1 biology.

A plausible mechanism is not the same as a clinical effect. An observational association is not the same as causation. And a promising early signal is not necessarily a viable treatment. The credibility of this field will depend on maintaining those distinctions.

The Missing Dimension: What Patients Report Experiencing

There is another dimension to this conversation that is easy to overlook. Clinical trials are designed to answer specific questions. Healthcare records capture diagnoses, prescriptions and coded outcomes. Pharmacovigilance systems capture adverse events.

None necessarily captures the full texture of how people experience a medicine.
What happens to someone’s relationship with food?
Do cravings change before weight does?
Does motivation feel different?
How do people describe changes in emotional eating, confidence, social behavior or wellbeing?

And which experiences are transient, which persist, and which may simply reflect the broader changes that accompany improved metabolic health? These are not substitutes for clinical endpoints. They are a different layer of evidence. This is where Patient data and social listening can become particularly valuable.

Analysis of Patient conversations can help identify emerging themes, understand how people describe their experiences and highlight questions that may not yet be captured in conventional datasets. For a medicine category evolving as quickly as GLP-1s, that matters.

Patient conversations may surface experiences or questions that could warrant further investigation alongside conventional clinical data.

The Bigger Question Behind the GLP-1 Story

One of the most interesting questions emerging from GLP-1 research may ultimately extend beyond weight loss itself. These medicines are creating an opportunity to investigate the relationship between metabolic health, the brain and behavior in a way that was previously difficult to study at scale.

The strongest current evidence provides reassurance around psychiatric safety. At the same time, emerging research is opening questions around depression, cognition, reward and addiction-related behaviors. Some findings are encouraging. Others remain inconclusive. And some compelling biological hypotheses have already failed to translate into clinical benefit.

That is exactly what makes this such an important area of research, where the next chapter should not be about finding a simple narrative for GLP-1s, It should be about building a more complete one.

For Talking Medicines, that means looking beyond the headline outcome and listening to people who discuss their experiences with these medicines in real life. Scientific evidence tells us what we know. Patient experience can help us understand what we still need to ask. And as the boundaries between metabolic and mental health research continue to evolve, those questions may prove just as important as the answers.

Connecting Emerging Research with Real-Life Experience

As research continues to explore the relationship between GLP-1s, metabolic health and mental wellbeing, understanding the real-life experiences of Patients and Consumers is increasingly important.

Discover how DrugVoice can help uncover emerging themes, understand changing perceptions and reveal the questions Patients and Consumers are asking about GLP-1s – adding a valuable human perspective to the evolving scientific evidence. Get in touch today to learn more.

References